help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajaj, M.
Right arrow Articles by DeFronzo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajaj, M.
Right arrow Articles by DeFronzo, R. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 1 200-206
Copyright © 2004 by The Endocrine Society

Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients

Mandeep Bajaj, Swangjit Suraamornkul, Paul Piper, Lou J. Hardies, Leonard Glass, Eugenio Cersosimo, Thongchai Pratipanawatr, Yoshinori Miyazaki and Ralph A. DeFronzo

Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7886

Address all correspondence and requests for reprints to: Mandeep Bajaj, M.D., Assistant Professor, Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284-7886. E-mail: mandeepbajaj{at}hotmail.com.

The effect of pioglitazone (PIO) on plasma adiponectin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) was studied in 11 type 2 diabetic patients (age, 52 ± 2 yr; body mass index, 29.6 ± 1.1 kg/m2; HbA1c, 7.8 ± 0.4%). HFC (magnetic resonance spectroscopy) and basal plasma adiponectin concentration were quantitated before and after PIO (45 mg/d) for 16 wk. Subjects received a 3-h euglycemic insulin (100 mU/m2·min) clamp combined with 3-[3H] glucose infusion to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO. PIO reduced fasting plasma glucose (10.0 ± 0.7 to 7.2 ± 0.6 mmol/liter, P < 0.01) and HbA1c (7.8 ± 0.4 to 6.5 ± 0.3%, P < 0.01) despite increased body weight (83.0 ± 3.0 to 86.4 ± 3.0 kg, P < 0.01). PIO improved Rd (6.6 ± 0.6 vs. 5.2 ± 0.5 mg/kg·min, P < 0.005) and reduced EGP (0.23 ± 0.04 to 0.05 ± 0.02 mg/kg·min, P < 0.01) during the 3-h insulin clamp. After PIO treatment, HFC decreased from 21.3 ± 4.2 to 11.0 ± 2.4% (P < 0.01), and plasma adiponectin increased from 7 ± 1 to 21 ± 2 µg/ml (P < 0.0001). Plasma adiponectin concentration correlated negatively with HFC (r = -0.60, P < 0.05) and EGP (r = -0.80, P < 0.004) and positively with Rd before (r = 0.68, P < 0.02) pioglitazone treatment; similar correlations were observed between plasma adiponectin levels and HFC (r = -0.65, P < 0.03) and Rd after (r = 0.70, P = 0.01) pioglitazone treatment. EGP was almost completely suppressed after pioglitazone treatment; taken collectively, plasma adiponectin concentration, before and after pioglitazone treatment, still correlated negatively with EGP during the insulin clamp (r = -0.65, P < 0.001). In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration. The increase in plasma adiponectin is strongly associated with a decrease in hepatic fat content and improvements in hepatic and peripheral insulin sensitivity. The increase in plasma adiponectin concentration after thiazolidinedione therapy may play an important role in reversing the abnormality in hepatic fat mobilization and the hepatic/muscle insulin resistance in patients with type 2 diabetes.

This work was supported in part by grants from Takeda America, National Institutes of Health Grant DK-24092, a Veterans Affairs Merit Award, and GCRC Grant MO1-RR01346.

Abbreviations: EGP, Endogenous glucose production; HbA1c, hemoglobin A1c; FFA, free fatty acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MRS, magnetic resonance spectroscopy; PPAR, peroxisome proliferator activator receptor; Rd, glucose disposal rate; Sf, fat resonance.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. Iozzo, R. Lautamaki, R. Borra, H.-R. Lehto, M. Bucci, A. Viljanen, J. Parkka, V. Lepomaki, R. Maggio, R. Parkkola, et al.
Contribution of Glucose Tolerance and Gender to Cardiac Adiposity
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4472 - 4482.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. A. Kassem and I. Raz
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
Diabetes Care, November 1, 2009; 32(suppl_2): S337 - S341.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
M. R. Dasu, S. Park, S. Devaraj, and I. Jialal
Pioglitazone Inhibits Toll-Like Receptor Expression and Activity in Human Monocytes and db/db Mice
Endocrinology, August 1, 2009; 150(8): 3457 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in GastroenterologyHome page
S. Chitturi
Review: Treatment options for nonalcoholic fatty liver disease
Therapeutic Advances in Gastroenterology, November 1, 2008; 1(3): 173 - 189.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
U. Khanderia, R. Pop-Busui, and K. A Eagle
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective
Ann. Pharmacother., October 1, 2008; 42(10): 1466 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Sattar and S. M. Nelson
Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3299 - 3301.
[Full Text] [PDF]

Home page
 DiabetesHome page
B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor
Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
Diabetes, September 1, 2008; 57(9): 2288 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
E. Horton, W. T. Cefalu, S. T. Haines, and L. M. Siminerio
Multidisciplinary Interventions: Mapping New Horizons in Diabetes Care
The Diabetes Educator, July 1, 2008; 34(Supplement_4): 78S - 89S.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. Koska, N. Stefan, P. A Permana, C. Weyer, M. Sonoda, C. Bogardus, S. R Smith, D. R Joanisse, T. Funahashi, J. Krakoff, et al.
Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals
Am. J. Clinical Nutrition, February 1, 2008; 87(2): 295 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Fernandez, C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo
Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms
Diabetes Care, January 1, 2008; 31(1): 121 - 127.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Z. Wang, M. M. Masternak, K. A. Al-Regaiey, and A. Bartke
Adipocytokines and the Regulation of Lipid Metabolism in Growth Hormone Transgenic and Calorie-Restricted Mice
Endocrinology, June 1, 2007; 148(6): 2845 - 2853.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
W. Li, J. Tonelli, P. Kishore, R. Owen, E. Goodman, P. E. Scherer, and M. Hawkins
Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1301 - E1307.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
D. B. Savage, K. F. Petersen, and G. I. Shulman
Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance
Physiol Rev, April 1, 2007; 87(2): 507 - 520.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo
Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
Thiazolidinediones improve beta-cell function in type 2 diabetic patients
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Sharma and B. Staels
Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
R. A Ajjan and P. J Grant
Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 147 - 158.
[Abstract] [PDF]

Home page
 NEJMHome page
R. Belfort, S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, et al.
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
N. Engl. J. Med., November 30, 2006; 355(22): 2297 - 2307.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Diabetes Care, November 1, 2006; 29(11): 2371 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. S. Burgert, S. E. Taksali, J. Dziura, T. R. Goodman, C. W. Yeckel, X. Papademetris, R. T. Constable, R. Weiss, W. V. Tamborlane, M. Savoye, et al.
Alanine Aminotransferase Levels and Fatty Liver in Childhood Obesity: Associations with Insulin Resistance, Adiponectin, and Visceral Fat
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4287 - 4294.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kankaanpaa, H.-R. Lehto, J. P. Parkka, M. Komu, A. Viljanen, E. Ferrannini, J. Knuuti, P. Nuutila, R. Parkkola, and P. Iozzo
Myocardial Triglyceride Content and Epicardial Fat Mass in Human Obesity: Relationship to Left Ventricular Function and Serum Free Fatty Acid Levels
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4689 - 4695.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Gastaldelli, Y. Miyazaki, A. Mahankali, R. Berria, M. Pettiti, E. Buzzigoli, E. Ferrannini, and R. A. DeFronzo
The Effect of Pioglitazone on the Liver: Role of adiponectin
Diabetes Care, October 1, 2006; 29(10): 2275 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Bajaj and O. Ben-Yehuda
A Big Fat Wedding: Association of Adiponectin With Coronary Vascular Lesions
J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1163 - 1165.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wang, K. S. L. Lam, L. Chan, K. W. Chan, J. B. B. Lam, M. C. Lam, R. C. L. Hoo, W. W. N. Mak, G. J. S. Cooper, and A. Xu
Post-translational Modifications of the Four Conserved Lysine Residues within the Collagenous Domain of Adiponectin Are Required for the Formation of Its High Molecular Weight Oligomeric Complex
J. Biol. Chem., June 16, 2006; 281(24): 16391 - 16400.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Buemann, A. Astrup, O. Pedersen, E. Black, C. Holst, S. Toubro, S. Echwald, J. J. Holst, C. Rasmussen, and T. I. A. Sorensen
Possible Role of Adiponectin and Insulin Sensitivity in Mediating the Favorable Effects of Lower Body Fat Mass on Blood Lipids
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
W. Verreth, J. Ganame, A. Mertens, H. Bernar, M.-C. Herregods, and P. Holvoet
Peroxisome Proliferator-Activated Receptor-{alpha},{gamma}-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 922 - 928.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Berria, L. Wang, D. K. Richardson, J. Finlayson, R. Belfort, T. Pratipanawatr, E. A. De Filippis, S. Kashyap, and L. J. Mandarino
Increased collagen content in insulin-resistant skeletal muscle
Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E560 - E565.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning
Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1
Endocrinology, February 1, 2006; 147(2): 875 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
F. Abbasi, S.-A. Chang, J. W. Chu, T. P. Ciaraldi, C. Lamendola, T. McLaughlin, G. M. Reaven, and P. D. Reaven
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R139 - R144.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Bajaj, S. Suraamornkul, A. Romanelli, G. W. Cline, L. J. Mandarino, G. I. Shulman, and R. A. DeFronzo
Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients
Diabetes, November 1, 2005; 54(11): 3148 - 3153.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. S. Reingold, J. M. McGavock, S. Kaka, T. Tillery, R. G. Victor, and L. S. Szczepaniak
Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method
Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E935 - E939.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Stefan, S. Schafer, F. Machicao, J. Machann, F. Schick, C. D. Claussen, M. Stumvoll, H.-U. Haring, and A. Fritsche
Liver Fat and Insulin Resistance Are Independently Associated with the -514C>T Polymorphism of the Hepatic Lipase Gene
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4238 - 4243.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Kamin, C. Hadigan, M. Lehrke, S. Mazza, M. A. Lazar, and S. Grinspoon
Resistin Levels in Human Immunodeficiency Virus-Infected Patients with Lipoatrophy Decrease in Response to Rosiglitazone
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3423 - 3426.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Bugianesi, U. Pagotto, R. Manini, E. Vanni, A. Gastaldelli, R. de Iasio, E. Gentilcore, S. Natale, M. Cassader, M. Rizzetto, et al.
Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3498 - 3504.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
F. Capozza, T. P. Combs, A. W. Cohen, Y.-R. Cho, S.-Y. Park, W. Schubert, T. M. Williams, D. L. Brasaemle, L. A. Jelicks, P. E. Scherer, et al.
Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle
Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1317 - C1331.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
Y.-H. Yu and H. N. Ginsberg
Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue
Circ. Res., May 27, 2005; 96(10): 1042 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-M. Petit, A. Minello, V. Jooste, J. B. Bour, F. Galland, L. Duvillard, B. Verges, N. O. Olsson, P. Gambert, and P. Hillon
Decreased Plasma Adiponectin Concentrations Are Closely Related to Steatosis in Hepatitis C Virus-Infected Patients
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2240 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. Punyadeera, A. H G Zorenc, R. Koopman, A. J McAinch, E. Smit, R. Manders, H. A Keizer, D. Cameron-Smith, and L. J C van Loon
The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle
Eur. J. Endocrinol., March 1, 2005; 152(3): 427 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. H. Tan, A. Baksi, B. Krahulec, P. Kubalski, A. Stankiewicz, R. Urquhart, G. Edwards, D. Johns, and for the GLAL Study Group
Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes
Diabetes Care, March 1, 2005; 28(3): 544 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. Pagano, G. Soardo, W. Esposito, F. Fallo, L. Basan, D. Donnini, G. Federspil, L. A Sechi, and R. Vettor
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Eur. J. Endocrinol., January 1, 2005; 152(1): 113 - 118.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
K. Nagao, N. Inoue, Y.-M. Wang, B. Shirouchi, and T. Yanagita
Dietary Conjugated Linoleic Acid Alleviates Nonalcoholic Fatty Liver Disease in Zucker (fa/fa) Rats
J. Nutr., January 1, 2005; 135(1): 9 - 13.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. G. Tolman, V. Fonseca, M. H. Tan, and A. Dalpiaz
Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus
Ann Intern Med, December 21, 2004; 141(12): 946 - 956.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, and R. A. DeFronzo
Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 Diabetes
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4649 - 4655.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society